Inside the research
Certara, Inc.
CERT Research profile · latest available data
Price overview
$9.11
▲ +0.22 (+2.5%)
| 52w hi | $13.60 |
|---|---|
| 52w lo | $4.48 |
| Vol | 2.92M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.11
| Short | +0.36 |
|---|---|
| Medium | +0.13 |
| Long | -0.46 |
computed 2026-09-27
Key fundamentals
Certara, Inc.
Healthcare · Health Information Services
| Market cap | $1.39B |
|---|---|
| Enterprise value | $1.51B |
| Forward P/E | 23.31x |
| EV / EBITDA | 15.99x |
| P / S (ttm) | 3.29x |
| Profit margin | -16.2% |
| Return on equity | -2.2% |
| Revenue growth | +1.0% |
| Debt / equity | 31.24 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.07 | |
| Sector | +0.08 | |
| Technical | +0.09 | |
| Earnings | +0.00 | |
| Sentiment | +0.21 |
macro × 1.00 · 2026-09-27
Business overview
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Risk Metrics
| Beta vs SPX | 0.95 |
|---|---|
| Corr SPX | 0.26 |
| Annual vol | 58.1% |
| Annual ret | +7.9% |
| Sharpe | 0.14 |
| Max DD | -69.0% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-07 | Reg FD Disclosure | read |
| 2026-08-04 | Earnings Release, Exhibits | read |
| 2026-08-04 | Officer / Director Change | read |
| 2026-06-17 | Officer / Director Change, Exhibits | read |
| 2026-05-15 | Shareholder Vote | read |
| 2026-05-11 | Earnings Release, Other Material Event… | read |
| 2026-04-22 | Material Agreement, Exhibits | read |
| 2026-03-31 | Officer / Director Change | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2025-12-11 | Officer / Director Change, Exhibits | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-10-16 | Material Agreement, Material Obligation… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-01 | Anhalt Rona | Officer, Chief Human Reso | Option exercise | 7.15K | — |
| 2026-06-01 | Anhalt Rona | Officer, Chief Human Reso | Withheld for tax | 2.24K | $13.04K |
| 2026-06-01 | Corcoran Daniel | Officer, SVP and General | Option exercise | 7.94K | — |
| 2026-06-01 | Corcoran Daniel | Officer, SVP and General | Withheld for tax | 4.21K | $24.50K |
| 2026-06-01 | Corcoran Daniel | Officer, SVP and General | Option exercise | 14.89K | — |
| 2026-06-01 | Corcoran Daniel | Officer, SVP and General | Withheld for tax | 7.89K | $45.94K |
| 2026-05-14 | Collins Cynthia | Director | Option exercise | 15.76K | — |
| 2026-05-14 | Reynders John V W | Director, Officer, Chief | Option exercise | 15.76K | — |
| 2026-05-14 | BROSHY ERAN | Director | Option exercise | 15.76K | — |
| 2026-05-14 | Bedi Arjun | Director | Option exercise | 5.55K | — |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 91.4% |
| HHI | 2,063 (moderate) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $31.58M | 4.82M |
| Capital Research / Capital World | $17.47M | 2.67M |
| Millennium Management | $16.74M | 2.56M |
| AQR Capital Management | $13.76M | 2.16M |
| Citadel Advisors | $7.16M | 1.09M |
| Renaissance Technologies | $4.48M | 684.70K |
| Norges Bank (Norway sovereign) | $3.41M | 519.90K |
| Fidelity / FMR LLC | $216.82K | 33.10K |
| T. Rowe Price Group | $1.15K | 176.09K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2021–2025 · 5 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $418.84M | +14.5% | |
| Operating income | -$40.77M | +28.8% | |
| Net income | -$1.59M | — | |
| Cash from ops | $80.47M | +15.8% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $8.95 | $9.20 | $8.73 | $9.11 | 2.92M |
| Sep 24 | $8.52 | $8.93 | $8.52 | $8.89 | 2.31M |
| Sep 23 | $8.82 | $9.12 | $8.59 | $8.64 | 2.59M |
| Sep 22 | $8.51 | $8.85 | $8.51 | $8.83 | 2.32M |
| Sep 21 | $8.49 | $8.64 | $8.43 | $8.52 | 1.89M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →